These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7571535)

  • 21. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome.
    Ozer F; Meral H; Aydin B; Hanoglu L; Aydemir T; Oral T
    J ECT; 2005 Jun; 21(2):125-7. PubMed ID: 15905757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment.
    Wolters EC
    Neurology; 1999; 52(7 Suppl 3):S10-3. PubMed ID: 10227604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacotoxic psychoses in patients with neurological disorders during old age (author's transl)].
    Danielczyk W
    Aktuelle Gerontol; 1979 Sep; 9(9):427-31. PubMed ID: 44122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombocytopenia associated with levodopa treatment.
    Giner V; Rueda D; Salvador A; Hernández JC; Esteban MJ; Redón J
    Arch Intern Med; 2003 Mar; 163(6):735-6. PubMed ID: 12639208
    [No Abstract]   [Full Text] [Related]  

  • 26. Hyponatraemia due to amantadine hydrochloride and L-dopa/carbidopa.
    Lammers GJ; Roos RA
    Lancet; 1993 Aug; 342(8868):439. PubMed ID: 8101938
    [No Abstract]   [Full Text] [Related]  

  • 27. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.
    Wolters EC; Hurwitz TA; Mak E; Teal P; Peppard FR; Remick R; Calne S; Calne DB
    Neurology; 1990 May; 40(5):832-4. PubMed ID: 1970427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?].
    Wedekind S
    MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622
    [No Abstract]   [Full Text] [Related]  

  • 29. Dopaminergic psychosis in advanced Parkinson's disease.
    Fischer P; Danielczyk W; Simanyi M; Streifler MB
    Adv Neurol; 1990; 53():391-7. PubMed ID: 2122647
    [No Abstract]   [Full Text] [Related]  

  • 30. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
    Arnold G; Trenkwalder C; Schwarz J; Oertel WH
    Mov Disord; 1994 Mar; 9(2):238-40. PubMed ID: 7910949
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hypersexuality during use of levodopa].
    van Deelen RA; Rommers MK; Eerenberg JG; Egberts AC
    Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2095-8. PubMed ID: 12448966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
    Koprich JB; Huot P; Fox SH; Jarvie K; Lang AE; Seeman P; Brotchie JM
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():151-6. PubMed ID: 23306217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Problem in prolonged levodopa administration of Parkinson disease patients--from the standpoint of the autonomic nervous function].
    Matsui TA; Nishikawa S; Saigo K; Kihara M; Takahashi M
    Rinsho Shinkeigaku; 1998 Apr; 38(4):295-300. PubMed ID: 9742874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
    Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
    Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease.
    Barbato L; Monge A; Stocchi F; Nordera G
    Funct Neurol; 1996; 11(4):201-7. PubMed ID: 8934152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 38. [Parkinson's disease].
    Yokochi M
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):5-14. PubMed ID: 10434578
    [No Abstract]   [Full Text] [Related]  

  • 39. [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
    Linazaroso G; van Blercom N; Lasa A
    Neurologia; 2004 Apr; 19(3):117-27. PubMed ID: 15088161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
    Thanvi B; Lo N; Robinson T
    Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.